Diabetes

Importantly, baseline gut microbiome profiles predicted changes in glycohaemoglobin among users of both therapies.

The system has been made available online, potentially enabling healthcare providers to rapidly assess CMM risk in patients with T2DM and implement timely interventions to slow disease progression.

A global meta-analysis shows people with mental disorders receive poorer diabetes monitoring and less access to newer therapies.

A major review links PFAS exposure to higher gestational diabetes risk, highlighting environmental chemicals as emerging pregnancy health concerns.

Among 469 circulating metabolites assessed, 235 were significantly associated with incident disease. Notably, 67 of these associations had not been previously reported.

Large cohort study links higher exposure to several food preservatives with increased type 2 diabetes incidence, prompting calls for safety review.

Evidence from a clinical trial and long-term cohort studies suggests metformin, widely used in diabetes, may reduce knee osteoarthritis pain and lower future osteoarthritis risk.

Mazdutide, a dual glucagon and GLP-1 agonist, delivers greater HbA1c and weight reductions than dulaglutide in people with type 2 diabetes.